Author

K. R. Brimacombe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 4 Organism:human· 3 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Approach:deep learning· 1 Organism:virus· 1

Frequent Co-Authors

M. D. Hall· 4 shared M. Shen· 4 shared A. Simeonov· 3 shared T. D. Lee· 3 shared B. Baljinnyam· 2 shared B. J. Poelaert· 2 shared C. Klumpp-Thomas· 2 shared D. M. Cheff· 2 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. D. Hall

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A deep learning framework for predicting the neutralizing activity of COVID-19 therapeutics and vaccines against evolving SARS-CoV-2 variants

R. P. Matson, I. Y. Comba, E. Silvert, M. J. Niesen, K. Murugadoss, D. Padwardhan, R. Suratekar, E.-G. Goel, B. J. Poelaert, K. Wan, K. R. Brimacombe, A. Venkatakrishnan, V. Soundararajan

This paper develops a deep learning model to predict neutralizing activity of COVID-19 therapeutics and vaccines against SARS-CoV-2 variants, finding reduced activity against newer variants like EG.5 and XBB.1.16.

bioRxiv · Oct 24, 2023 · PreprintImmunology

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry

A High-Throughput Screen of a Library of Therapeutics Identifies Substrates of P-glycoprotein

T. D. Lee, O. W. Lee, K. R. Brimacombe, L. Chen, R. Guha, S. Lusvarghi, B. G. Tebase, C. Klumpp-Thomas, R. W. Robey, S. V. Ambudkar, M. Shen, M. M. Gottesman, M. D. Hall

This paper identifies 90 P-gp substrates from 10,804 compounds using a high-throughput screen, including 55 new substrates confirmed by orthogonal assays.

bioRxiv · Jan 23, 2019Pharmacology & Toxicology

Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors

J. M. Rohde, K. R. Brimacombe, L. Liu, M. E. Pacold, A. Yasgar, D. M. Cheff, T. D. Lee, G. Rai, B. Baljinnyam, Z. Li, A. Simeonov, M. D. Hall, M. Shen, D. M. Sabatini, M. B. Boxer

The paper develops a biochemical assay to screen for PHGDH inhibitors, identifies piperazine-1-thiourea compounds, and evaluates their biological impact on serine metabolism in cancer cells.

Bioorganic & Medicinal Chemistry · May 1, 2018Peer-reviewedCancer Biology

Assessing Inhibitors Of Mutant Isocitrate Dehydrogenase Using A Suite Of Pre-Clinical Discovery Assays

D. J. Urban, N. J. Martinez, M. I. Davis, K. R. Brimacombe, D. M. Cheff, T. D. Lee, M. J. Henderson, S. A. Titus, R. Pragani, J. M. Rohde, Y. Wang, S. Karavadhi, P. Shah, O. W. Lee, A. Wang, , M. D. Hall

The paper evaluates inhibitors of mutant IDH1 and IDH2 using biochemical and cell-based assays to identify effective compounds for cancer therapy.

bioRxiv · Apr 7, 2017Cancer Biology